Physician profile
Shelly Nanda
NPI 1598710584
$604.43
in general payments reported to CMS, 2019-2025
13 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.76 · 2021: $16.68 · 2024: $87.38 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.72 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.92 | 2024-2025 | |
| Allergan, INC. | $82.76 | 2020 | |
| Novo Nordisk INC | $73.85 | 2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $72.01 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $60.27 | 2025 | Rexulti |
| Pfizer INC. | $48.65 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $29.37 | 2025 | Zoryve |
| Abbott Laboratories | $23.16 | 2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $19.79 | 2025 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $19.26 | 2025 | Acthar |
| Aimmune Therapeutics, INC. | $18.11 | 2025 | Zenpep |
| Optos, INC. | $16.68 | 2021 | |
| Philips North America LLC | $15.60 | 2025 | Extended Holter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.